CORDIS
EU research results

CORDIS

English EN

Gene overdosage and comorbidities during the early lifetime in Down Syndrome

Project information

Grant agreement ID: 848077

Status

Ongoing project

  • Start date

    1 January 2020

  • End date

    31 December 2024

Funded under:

H2020-EU.3.1.1.

  • Overall budget:

    € 5 965 967,75

  • EU contribution

    € 5 965 967,75

Coordinated by:

CENTRE EUROPEEN DE RECHERCHE EN BIOLOGIE ET MEDECINE

France

Project description

English EN

Obesity and intellectual disability may result from a genetic 'overdose'

All the genetic material our body requires to make all its proteins is located on 23 paired chromosomes. They contain the code for all the proteins our body makes. All cells carry the entire code, but specific cells express specific proteins according to their functions. Down's syndrome, also known as trisomy-21, is a genetic disorder in which a person has three copies of chromosome 21 instead of the usual two. It is associated with a high risk of both severe obesity and intellectual disorder. On the hypothesis that the locus may be on chromosome 21, the EU-funded GO-DS21 project is investigating the genetic mechanisms of this comorbidity. Outcomes should benefit patients with Down's syndrome and the general population.

Coordinator

CENTRE EUROPEEN DE RECHERCHE EN BIOLOGIE ET MEDECINE

Address

Rue Laurent Fries 1
67404 Illkirch Graffenstaden

France

Activity type

Research Organisations

EU Contribution

€ 1 029 185

Participants (11)

INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE

France

EU Contribution

€ 540 000

FUNDACIO CENTRE DE REGULACIO GENOMICA

Spain

EU Contribution

€ 554 556,25

KING'S COLLEGE LONDON

United Kingdom

EU Contribution

€ 567 998,75

QUEEN MARY UNIVERSITY OF LONDON

United Kingdom

EU Contribution

€ 579 885

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH

Germany

EU Contribution

€ 928 025

INSTITUT JEROME LEJEUNE

France

EU Contribution

€ 344 043,75

Concentris Research Management GmbH

Germany

EU Contribution

€ 370 000

FUNDACIO INSTITUT MAR D INVESTIGACIONS MEDIQUES IMIM

Spain

EU Contribution

€ 391 744

THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

EU Contribution

€ 440 530

TRISOMY 21 RESEARCH SOCIETY

Netherlands

EU Contribution

€ 20 000

PERHA PHARMACEUTICALS SAS

France

EU Contribution

€ 200 000

Project information

Grant agreement ID: 848077

Status

Ongoing project

  • Start date

    1 January 2020

  • End date

    31 December 2024

Funded under:

H2020-EU.3.1.1.

  • Overall budget:

    € 5 965 967,75

  • EU contribution

    € 5 965 967,75

Coordinated by:

CENTRE EUROPEEN DE RECHERCHE EN BIOLOGIE ET MEDECINE

France